LACTOLOGY FOUNDATION

A10AB06 — Insulin Glulisine: Academic Toxicological and Lactological Monograph

1. ATC Classification and Pharmacological Profile

A10AB06 designates insulin glulisine, a rapid-acting recombinant insulin analogue classified within A10 (Drugs used in diabetes), A10A (Insulins and analogues), and A10AB (Insulins and analogues for injection, fast-acting). The WHO ATC/DDD Index assigns insulin glulisine a parenteral defined daily dose (DDD) of 40 units. As with other ATC-defined DDDs, this value is intended for drug-utilization statistics and does not represent an individualized therapeutic dose. ATCDDD

Insulin glulisine is a recombinant analogue of human insulin. It is produced by recombinant DNA technology and has two amino-acid substitutions relative to human insulin: asparagine at position B3 is replaced by lysine, and lysine at position B29 is replaced by glutamic acid. These modifications favor rapid absorption after subcutaneous administration while preserving insulin-receptor agonist activity. Current authorized preparations contain recombinant insulin glulisine, commonly at a concentration of 100 units/mL. Medicines.org.uk

Pharmacodynamically, insulin glulisine binds to insulin receptors and produces the characteristic metabolic effects of insulin. It promotes peripheral glucose uptake, particularly in skeletal muscle and adipose tissue, inhibits hepatic glucose production, suppresses lipolysis and proteolysis, and facilitates anabolic processes including glycogen and protein synthesis.

Its principal distinguishing feature is its rapid prandial action. Following subcutaneous administration, absorption is faster than that of regular human insulin; pharmacokinetic studies demonstrate an earlier time to peak concentration. This rapid profile permits administration in close temporal relationship to meals and makes insulin glulisine suitable as the prandial component of individualized insulin regimens. PubChem

The WHO has classified insulin glulisine together with insulin lispro and insulin aspart as a rapid-acting insulin analogue. The distinction between rapid-acting analogues and short-acting regular human insulin is pharmacokinetically important even though both categories function clinically as bolus insulins. World Health Organization

From a lactological perspective, insulin glulisine retains the fundamental characteristics of a peptide insulin molecule. Thus, its evaluation differs substantially from that of orally bioavailable small-molecule drugs: even when transferred into human milk, gastrointestinal degradation greatly restricts systemic exposure of the breastfed infant.

2. Toxicological Profile

The principal toxicological hazard of insulin glulisine is hypoglycemia caused by excessive pharmacological insulin activity. Toxicity therefore represents an extension of its therapeutic mechanism rather than intrinsic cytotoxicity.

Hypoglycemia may arise from excessive dosing, inadequate carbohydrate intake, delayed or missed meals, increased physical activity, changes in insulin sensitivity, renal or hepatic dysfunction, intercurrent illness, medication interactions, or insulin-administration errors. Because insulin glulisine has rapid prandial activity, inappropriate coordination between dosing and food intake may precipitate an acute glucose decline.

Mild or moderate hypoglycemia can produce hunger, sweating, tremor, palpitations, anxiety, weakness, dizziness, and impaired concentration. Progressive neuroglycopenia may manifest as behavioral changes, confusion, visual disturbances, impaired coordination, seizures, unconsciousness, or coma. Severe or prolonged hypoglycemia can result in neurological injury and may be fatal.

Substantial insulin excess can additionally cause hypokalemia because insulin stimulates cellular potassium uptake. Severe hypokalemia can produce muscle weakness, cardiac electrophysiological abnormalities, arrhythmias, and other potentially serious complications.

Other class-consistent adverse effects include injection-site reactions, lipohypertrophy or lipoatrophy, weight gain, edema, and hypersensitivity reactions. Repeated injections into areas of lipodystrophy can produce unpredictable absorption and increase glycemic variability. Although recombinant insulin analogues have relatively low immunogenic potential, antibody formation and allergic reactions remain possible.

Medication errors involving insulin concentration, dose, preparation, or delivery device constitute an important preventable source of toxicity. Such errors may cause profound hypoglycemia or, when insufficient insulin is administered, severe hyperglycemia and metabolic decompensation.

During lactation, maternal hypoglycemia is considerably more clinically relevant than milk-mediated infant toxicity. According to the updated 2026 LactMed review, insulin requirements in women with type 1 diabetes are generally about 30–50% lower than prepregnancy doses immediately postpartum. Requirements during breastfeeding average approximately 21% below prepregnancy levels in reported data, although variability is wide and postpartum requirements do not consistently differ between breastfeeding and non-breastfeeding women. NCBI

Severe maternal hypoglycemia additionally creates an indirect infant-safety concern because impaired consciousness, coordination, or judgment may interfere with safe breastfeeding and infant care.

3. Lactation Pharmacology and Breast-Milk Exposure

Insulin is a normal physiological component of human breast milk, and exogenous insulin can also be transferred into milk. Importantly for A10AB06, the current LactMed review explicitly identifies insulin glulisine among newer biosynthetic insulins that are excreted into breast milk. NCBI

However, detailed substance-specific pharmacokinetic information for insulin glulisine in lactating women remains limited. Published data do not provide sufficiently comprehensive glulisine-specific milk concentration curves, milk-to-plasma ratios, or validated relative infant dose estimates to permit the type of quantitative exposure assessment routinely performed for many small-molecule drugs.

This limitation should not be interpreted as evidence of significant uncertainty regarding systemic infant toxicity. The fundamental pharmacology of insulin provides a strong mechanistic basis for risk assessment.

Insulin glulisine is a peptide molecule. After ingestion in breast milk, it is expected to undergo proteolytic degradation within the infant gastrointestinal tract, resulting in extremely low systemic oral bioavailability. Therefore, the amount of insulin glulisine swallowed in milk does not correspond to the amount reaching the infant's systemic circulation in pharmacologically active form.

For the same reason, conventional relative infant dose (RID) calculations have limited clinical relevance. A milk-derived RID would estimate the amount swallowed but could markedly overstate biologically active systemic exposure because it would not adequately represent gastrointestinal destruction of the peptide.

This distinction between milk transfer and systemic infant exposure is central to the lactological assessment of insulin glulisine. Detection or expected presence of glulisine in breast milk does not imply that the breastfed infant receives an insulin dose comparable to parenteral exposure.

Further reassurance comes from experience with enteral insulin itself. LactMed notes that recombinant insulin has been administered orally to premature infants without establishing a systemic safety concern. NCBI

Insulin in human milk also has physiological significance beyond pharmaceutical exposure. Milk insulin has been investigated in relation to intestinal maturation and metabolic development. These observations, however, should not be extrapolated to suggest that increasing maternal insulin glulisine exposure provides an additional therapeutic benefit to the breastfed infant.

4. Effects in the Breastfed Infant and on Lactation

No established pattern of clinically significant adverse effects in breastfed infants has been attributed specifically to therapeutic maternal insulin glulisine. The 2026 LactMed review reports that relevant published information concerning adverse effects of insulin in breastfed infants remains lacking, while explicitly concluding that mothers with diabetes who use insulin may breastfeed. NCBI

In particular, clinically meaningful infant hypoglycemia caused by insulin glulisine in breast milk is not expected. Although glulisine may be excreted into milk, gastrointestinal proteolysis and negligible oral systemic bioavailability make absorption of a pharmacologically significant insulin dose highly improbable.

There is likewise no established evidence that maternal insulin glulisine exposure through breast milk adversely affects infant growth or development. Nevertheless, glulisine-specific prospective lactation studies remain comparatively sparse; therefore, the favorable assessment is supported primarily by peptide pharmacology, class-level insulin evidence, and accumulated clinical experience rather than extensive substance-specific infant pharmacokinetic studies.

The relationship between insulin therapy and lactation itself is more clinically relevant. Physiological insulin activity is necessary for normal mammary metabolism. LactMed reports that good maternal glycemic control enhances maternal serum and milk prolactin responses and reduces the delay in establishment of lactation that may occur in women with type 1 diabetes. NCBI

Women with diabetes may nevertheless experience delayed lactogenesis or low milk supply more frequently than women without diabetes. LactMed also notes that women with diabetes during pregnancy have reported more problems with low milk supply and that insulin-treated gestational diabetes has been associated with delayed lactogenesis II and lower exclusive breastfeeding rates. These associations should not be interpreted as evidence that insulin glulisine directly suppresses lactation. Underlying diabetes, metabolic control, obstetric factors, earlier delivery, maternal characteristics, and other clinical variables can contribute. NCBI

Once established, lactation can persist normally in women with diabetes. Appropriate insulin treatment should therefore be regarded as an essential component of maternal metabolic management rather than as an impediment to breastfeeding.

5. Lactological Safety Assessment and Clinical Recommendations

Insulin glulisine (A10AB06) is compatible with breastfeeding. The updated LactMed review explicitly includes glulisine among newer biosynthetic insulins excreted into breast milk and states that mothers with diabetes requiring insulin may nurse their infants. NCBI

The favorable assessment rests on several mutually reinforcing considerations: insulin is physiologically present in human milk; exogenous insulin glulisine may enter milk; glulisine is a peptide susceptible to gastrointestinal proteolysis; systemic oral bioavailability is negligible; and no clinically significant pattern of infant toxicity attributable to maternal therapy has been established.

Consequently, insulin glulisine therapy does not ordinarily require interruption of breastfeeding, discarding expressed milk, or replacement of breastfeeding with formula feeding.

Deliberate timing of breastfeeding around individual insulin glulisine injections is also unnecessary for the purpose of minimizing infant exposure. Even if milk concentrations vary after maternal administration, the decisive protective factor is the extremely low systemic absorption of orally ingested insulin rather than avoidance of a theoretical peak milk concentration.

Routine measurement of blood glucose in a healthy term breastfed infant is not indicated solely because the mother receives insulin glulisine. Premature, medically unstable, or metabolically vulnerable infants should be assessed according to their underlying clinical circumstances, but maternal glulisine exposure alone does not constitute evidence of a need for routine biochemical surveillance.

Clinical management should instead prioritize maternal postpartum glycemic control. Insulin doses should be reassessed promptly after delivery because insulin requirements may fall substantially. Subsequent dosing should be individualized according to glucose monitoring, carbohydrate intake, breastfeeding pattern, physical activity, renal and hepatic function, intercurrent illness, and changes in insulin sensitivity. NCBI

Mothers should be familiar with the symptoms and management of hypoglycemia and should have rapidly absorbable carbohydrate readily accessible. Particular vigilance is appropriate during the early postpartum period, overnight infant care, periods of reduced caloric intake, increased physical activity, or substantial changes in breastfeeding frequency.

Continuous glucose monitoring or appropriately frequent capillary glucose assessment may facilitate safe dose adjustment where clinically indicated. Recurrent or severe hypoglycemia requires reassessment of insulin dose, meal timing, glucose targets, and other contributing factors.

Thus, the clinical benefit–risk balance strongly favors continuing necessary insulin glulisine therapy while supporting breastfeeding, with safety measures directed principally toward maternal metabolic management rather than avoidance of clinically negligible infant exposure.

6. Conclusion

A10AB06 insulin glulisine is a rapid-acting recombinant insulin analogue used for prandial glucose control. It is classified by WHO among fast-acting injectable insulins and analogues, with a parenteral DDD of 40 units. ATCDDD

Its principal toxicological hazard is excessive pharmacological activity producing hypoglycemia. Significant insulin excess may additionally cause hypokalemia, while other recognized adverse effects include injection-site reactions, lipodystrophy, weight gain, edema, antibody formation, and hypersensitivity.

From a lactological perspective, insulin glulisine has a favorable safety profile. Exogenous glulisine can be excreted into breast milk, but insulin is itself a physiological milk constituent. More importantly, insulin glulisine is a peptide subject to gastrointestinal degradation, so clinically meaningful systemic absorption by the breastfed infant is highly unlikely. The current LactMed review explicitly includes insulin glulisine among biosynthetic insulins compatible with nursing. NCBI

No established evidence indicates clinically significant infant hypoglycemia or other systemic toxicity resulting from therapeutic maternal insulin glulisine. Routine breastfeeding interruption, disposal of expressed milk, dose-to-feed separation, or glucose monitoring of healthy term infants is therefore unnecessary solely because of maternal A10AB06 therapy.

The principal lactation-associated consideration is instead individualized maternal insulin adjustment after delivery, when insulin requirements may decrease substantially and subsequently evolve as maternal metabolism, nutrition, and breastfeeding patterns change.

Overall, insulin glulisine is compatible with breastfeeding, and clinically necessary maternal therapy should be maintained. Lactological management should focus on effective maternal glycemic control and prevention of maternal hypoglycemia rather than concern about clinically insignificant breast-milk exposure of the infant.